Drug Approval | January 17, 2022
Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection
The company has 47 ANDA's pending approval with the U.S.FDA
The company has 47 ANDA's pending approval with the U.S.FDA
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
It is the first monoclonal antibody drug for use in any animal species
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The stability is led by healthy demand in the domestic and emerging markets
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Subscribe To Our Newsletter & Stay Updated
